Notes
Funding for this study was provided by Thermo Fisher Scientific, US.
Reference
Yu TM, et al. Budget Impact of Next Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMD23, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71521?pdfid=50325
Rights and permissions
About this article
Cite this article
NGS worthwhile for molecular assessment in aNSCLC. PharmacoEcon Outcomes News 780, 26 (2017). https://doi.org/10.1007/s40274-017-4078-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4078-5